Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.

[1]  S. Faust,et al.  Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial , 2015, BMJ : British Medical Journal.

[2]  A. Pollard,et al.  Evaluation of the Induction of Immune Memory following Infant Immunisation with Serogroup C Neisseria meningitidis Conjugate Vaccines – Exploratory Analyses within a Randomised Controlled Trial , 2014, PloS one.

[3]  T. Odrljin,et al.  Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in Adolescents , 2013, The Pediatric infectious disease journal.

[4]  R. Read,et al.  Serum Antibody Kinetics following Nasal or Parenteral Challenge with Meningococcal Polysaccharide in Healthy Adults , 2011, Clinical and Vaccine Immunology.

[5]  J. van de Kassteele,et al.  Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults. , 2009, Vaccine.

[6]  D. Kelly,et al.  Plasma and memory B‐cell kinetics in infants following a primary schedule of CRM197‐conjugated serogroup C meningococcal polysaccharide vaccine , 2009, Immunology.

[7]  S. Lockhart,et al.  Demonstration of Immunologic Memory Using Serogroup C Meningococcal Glycoconjugate Vaccine , 2009, The Pediatric infectious disease journal.

[8]  D. Kelly,et al.  The Magnitude of the Antibody and Memory B Cell Responses during Priming with a Protein-Polysaccharide Conjugate Vaccine in Human Infants Is Associated with the Persistence of Antibody and the Intensity of Booster Response1 , 2008, The Journal of Immunology.

[9]  A. Pollard,et al.  Reconsideration of the Use of Meningococcal Polysaccharide Vaccine , 2007, The Pediatric infectious disease journal.

[10]  N. Andrews,et al.  Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. , 2006, The Journal of infectious diseases.

[11]  D. Kelly,et al.  Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  H. Gnehm,et al.  Early Appearance of Bactericidal Antibodies after Polysaccharide Challenge of Toddlers Primed with a Group C Meningococcal Conjugate Vaccine: What Is Its Role in the Maintenance of Protection? , 2006, Clinical and Vaccine Immunology.

[13]  Elizabeth Miller,et al.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction , 2004, The Lancet.

[14]  A. Larrauri,et al.  Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. , 2004, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  David Goldblatt,et al.  Immunogenicity of, and Immunologic Memory to, a Reduced Primary Schedule of Meningococcal C-Tetanus Toxoid Conjugate Vaccine in Infants in the United Kingdom , 2003, Infection and Immunity.

[16]  M. Ramsay,et al.  Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. , 2001, Vaccine.

[17]  N. Andrews,et al.  Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls. , 2001, Vaccine.

[18]  N. Begg,et al.  Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine , 2000, Epidemiology and Infection.

[19]  E. Miller,et al.  Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. , 2000, The Journal of infectious diseases.

[20]  N. Begg,et al.  Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. , 1999, The Journal of infectious diseases.

[21]  D. Granoff,et al.  Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. , 1998, JAMA.

[22]  P. De Wals,et al.  Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts. , 1981, The Journal of infection.

[23]  E. Gotschlich,et al.  Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. , 1977, The Journal of infectious diseases.

[24]  H. Ward,et al.  Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. , 1977, Scandinavian journal of infectious diseases.